Locoregional tumor failure after definitive radiation for patients with stage III non-small cell lung cancer

被引:15
|
作者
Rajpara, Raj S.
Schreibmann, Eduard
Fox, Tim
Stapleford, Liza J.
Beitler, Jonathan J.
Curran, Walter J.
Higgins, Kristin A. [1 ]
机构
[1] Emory Univ, Sch Med, Dept Radiat Oncol, Atlanta, GA 30322 USA
来源
RADIATION ONCOLOGY | 2014年 / 9卷
关键词
Lung cancer; Locally advanced; Locoregional failure; PET/CT; Radiation; Chemotherapy; STANDARDIZED UPTAKE VALUE; PHASE-III; CONCURRENT CHEMOTHERAPY; FDG-PET; TRIAL; RADIOTHERAPY; INDUCTION; SURVIVAL; THERAPY; DISEASE;
D O I
10.1186/1748-717X-9-187
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Locoregional tumor failure (LRF) after definitive chemoradiation for patients with stage III NSCLC remains unacceptably high. This analysis sought to further define where LRF occurs relative to radiation dose received and pre-treatment PET scan-defined maximum standard uptake value (SUVmax). Methods: This was a retrospective study analyzing patients with stage III NSCLC treated with definitive radiation between 2006 and 2011. LRF was defined as failure within the ipsilateral lung, hilum or mediastinum. The CT simulation scan with the radiation dose distribution was registered to the CT or PET/CT documenting LRF. The region of LRF was contoured, and the dose to 95% of the volume (D95) of LRF was extracted. The pre-treatment SUVmax was also extracted for the anatomic region of LRF. Results: Sixty-one patients were identified. Median follow-up time was 19.1 months (range 2.37-76.33). Seventy four percent of patients were treated with 3-D conformal technique (3DCRT), 15% were treated with Intensity Modulated Radiotherapy (IMRT), and 11% were treated with a combination of 3DCRT and IMRT. Median prescribed radiation dose for all patients was 66 Gy (39.6-74). Concurrent chemotherapy was delivered in 90% of patients. Twenty-two patients (36%) developed a LRF, with a total of 39 anatomic regions of LRF identified. Median time to LRF was 11.4 months (3.5-44.6). Failures were distributed as follows: 36% were in-field failures, 27% were out-of-field failures, 18% were in-field and out-of-field failures, and 18% were in-field and marginal (recurrences within the field edge) failures. There were no isolated marginal failures. Of the patients that developed a LRF, 73% developed a LRF with an in-field component. Sixty-two percent of LRFs were nodal. The median pre-treatment SUVmax for the anatomic region of LRF for patients with an in-field failure was 13. The median D95 of in-field LRF was 63 Gy. Conclusions: LRF after definitive chemoradiation are comprised primarily of in-field failures, though out-of field failures are not insignificant. Marginal failures are rare, indicating field margins are appropriate. Although radiation dose escalation to standard radiation fields has not yielded success, using PET parameters to define high-risk regions remains worthy of further investigation.
引用
收藏
页数:7
相关论文
共 50 条
  • [21] Stage III Non-Small Cell Lung Cancer Clinical Outcomes with Surgical Resection After Definitive Neoadjuvant Chemoradiotherapy
    Caturegli, I.
    Vyfhuis, M.
    Burrows, W.
    Suntharalingam, M.
    Badiyan, S.
    Scilla, K.
    Carr, S.
    Friedberg, J.
    Henry, G.
    Stewart, S.
    Ii, C. Simone
    Mohindral, P.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S462 - S463
  • [22] Durvalumab after chemoradiotherapy in stage III non-small cell lung cancer
    Tomasini, Pascale
    Greillier, Laurent
    Boyer, Arnaud
    Jeanson, Arnaud
    Barlesi, Fabrice
    JOURNAL OF THORACIC DISEASE, 2018, 10 : S1032 - S1036
  • [23] Non-small cell lung cancer: Radiation therapy for locoregional recurrence after complete resection
    Tada T.
    Fukuda H.
    Nakagawa K.
    Matsui K.
    Hosono M.
    Takada Y.
    Inoue Y.
    International Journal of Clinical Oncology, 2005, 10 (6) : 425 - 428
  • [24] Distant failure after treatment of postoperative locoregional recurrence of non-small cell lung cancer
    Hotta, K
    Sekine, I
    Suzuki, K
    Hondo, H
    Asamura, H
    Sumi, M
    Yamamoto, N
    Kunitoh, H
    Ohe, Y
    Tamura, T
    Kodama, T
    Saijo, N
    Tsuchiya, R
    THORACIC AND CARDIOVASCULAR SURGEON, 2003, 51 (05): : 283 - 287
  • [25] Stage and treatment migration in patients with stage III non-small cell lung cancer
    Hubbs, J. L.
    Fatunase, T.
    Hollis, D. R.
    Clough, R. W.
    Kelsey, C. R.
    D'Amico, T. A.
    Marks, L. B.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2007, 69 (03): : S159 - S160
  • [26] How do lung cancer specialists follow their patients with stage III non-small cell lung cancer (NSCLC) after definitive treatment? - A short report
    Yumuk, Perran Fulden
    Mohammed, Nazia
    Maat, Alexander P. W. M.
    Fink, Christian
    Marchal, Benedicte
    O'Brien, Mary E. R.
    EUROPEAN JOURNAL OF CANCER, 2012, 48 (14) : 2163 - 2165
  • [27] Dosimetric benefits of adaptive radiation therapy for patients with stage III non-small cell lung cancer
    Lea Hoppen
    Gustavo R. Sarria
    Chung S. Kwok
    Judit Boda-Heggemann
    Daniel Buergy
    Michael Ehmann
    Frank A. Giordano
    Jens Fleckenstein
    Radiation Oncology, 18
  • [28] Dosimetric benefits of adaptive radiation therapy for patients with stage III non-small cell lung cancer
    Hoppen, Lea
    Sarria, Gustavo R.
    Kwok, Chung S.
    Boda-Heggemann, Judit
    Buergy, Daniel
    Ehmann, Michael
    Giordano, Frank A.
    Fleckenstein, Jens
    RADIATION ONCOLOGY, 2023, 18 (01)
  • [29] Impact of Early Tumor Regression on Outcome Is Different by Histological Subtype in Stage III Non-Small Cell Lung Cancer Treated With Definitive Radiation Therapy
    Kanzaki, H.
    Kataoka, M.
    Noriko, N.
    Nagasaki, K.
    Uwatsu, K.
    Nishikawa, A.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2015, 93 (03): : E446 - E446
  • [30] Registry Based Analysis of Radiation Modality on Survival with Definitive Chemoradiation for Stage III Non-Small Cell Lung Cancer (NSCLC)
    Gross, A.
    Kharouta, M.
    Biswas, T.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (03) : E39 - E39